Improving the care of our patients who are receiving glucocorticoid therapy

Archives of Dermatology

Volumn 148, Issue 3, 2012, Pages 314-315

  Albrecht, Joerg ^a   Werth, Victoria P ^b,c  

^a Jr Hospital of Cook County   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ALENDRONIC ACID; ANTIINFLAMMATORY AGENT; BONE DENSITY CONSERVATION AGENT; PREDNISOLONE;

CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; DRUG USE; FEMUR FRACTURE; HUMAN; JAW OSTEONECROSIS; PATIENT ASSESSMENT; PATIENT CARE; PATIENT IDENTIFICATION; PATIENT SELECTION; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT SURVEY; VITAMIN SUPPLEMENTATION; AUTOIMMUNE DISEASE; BULLOUS SKIN DISEASE; CHEMICALLY INDUCED DISORDER; FEMALE; MALE; NOTE; OSTEOPOROSIS;

ALENDRONATE; ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; BONE DENSITY CONSERVATION AGENTS; FEMALE; HUMANS; MALE; OSTEOPOROSIS; PREDNISOLONE; SKIN DISEASES, VESICULOBULLOUS;

EID: 84858717756     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.2715     Document Type: Short Survey

References (3)

1. Tee S-I, Yosipovitch G, Chan YC, et al. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study [published online November 21, 2011]. Arch Dermatol. 2012;148(3):307-314.
2. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62(11):1515-1526.
3. Wallace AW, Amsden GW. Is it really OK to take this with food? old interactions with a new twist. J Clin Pharmacol. 2002;42(4):437-443. (Pubitemid 34259778)